HomeBUSINESS
BUSINESS

Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
(Dec.1.2017)

Chugai Pharmaceutical and Hiroshima University spinoff TWOCELLS said on November 29 that surgery was performed on the first patient in a PIII study of a regenerative cellular medicine for chondrogenesis in the knee (development code: gMSC1) conducted by the startup. Chugai concluded a license agreement with the startup for the agent in 2016 ...
(LOG IN FOR FULL STORY)